Intravitreal Bevacizumab in Treatment of Idiopathic Persistent Central Serous Chorioretinopathy: A Prospective, Controlled Clinical Study

Author： Artunay Ozgur   Yuzbasioglu Erdal   Rasier Rifat   Sengul Alper   Bahcecioglu Halil  

Publisher： Informa Healthcare

ISSN： 0271-3683

Source： Current Eye Research, Vol.35, Iss.2, 2010-02, pp. : 91-98

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intravitreal Bevacizumab to Treat Acute Central Serous Chorioretinopathy: Short-Term Effect

By  

Ophthalmologica, Vol. 223, Iss. 5, 2009-06 ,pp. : 343-347

Karger

Access to resources Recommend Favorite

Results of One-Year Follow-Up Examinations after Intravitreal Bevacizumab Administration for Chronic Central Serous Chorioretinopathy

By  

Ophthalmologica, Vol. 225, Iss. 1, 2010-08 ,pp. : 37-40

Karger

Access to resources Recommend Favorite

Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy

By  

Case Reports in Ophthalmology, Vol. 5, Iss. 2, 2014-07 ,pp. : 207-211

Karger

Access to resources Recommend Favorite

Intravitreal Bevacizumab for Photodynamic Therapy-Induced Massive Macular Detachment in Acute Central Serous Chorioretinopathy

By  

Case Reports in Ophthalmology, Vol. 3, Iss. 2, 2012-06 ,pp. : 196-199

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab for Acute Central Serous Chorioretinopathy

By  

Ophthalmologica, Vol. 229, Iss. 3, 2012-12 ,pp. : 152-157

Karger

Access to resources Recommend Favorite